secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001558370-24-015168
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KALA BIO Q3 net loss $9.0M; cash $49.2M; Phase 2b topline due 2Q 2025
---------------------------------------------------------------------

- Net loss $9.0M ($1.93/share) in Q3 2024 vs $8.7M ($3.41) in Q3 2023.
- Cash $49.2M as of Sep 30, 2024; funding expected into Q4 2025; includes $3.2M from CIRM.
- R&D $5.2M, G&A $4.4M; operating loss $10.0M in Q3 2024.
- Phase 2b CHASE trial for PCED enrolling; topline data expected 2Q 2025; five sites in Argentina.
- Exploring KPI-012 for LSCD (est. 100k patients); preclinical KPI-014 for inherited retinal diseases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837024015168/0001558370-24-015168-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837024015168/kala-20241112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015168

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer